LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)
| Autor: | N. Tannir, M.N. Formiga, N. Agarwal, S.K. Pal, D. Cho, D.J. George, W. Hong, L. Tang, A. Qureshi, M.A. Tagliaferri, J. Zalevsky, K.D. Penkov |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Annals of Oncology. 33:S1433 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/j.annonc.2022.08.073 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|